• Xlife Sciences published annual report for 2025, highlighting major portfolio moves and capital-markets preparations.
• Group signed binding declaration with Grupo Landsteiner to combine 12 portfolio companies into a US joint venture targeting NASDAQ listing, with strategic value of USD 450 million.
• Veraxa advanced its planned NASDAQ route for 2026 through Voyager Acquisition Corp., supported by new preclinical data from its BiTAC platform showing stronger tumor activity with lower toxicity versus competitors.
• Saniva completed 2 clinical studies for its NeuroMex Alzheimer screening program, shifting focus to market launch preparation or partnering.
• Xlife moved from SIX Sparks to SIX main segment in Q1 2026 to improve share liquidity and broaden institutional access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.